

**Bio<sup>®</sup> China**

The BIO  
International  
Convention  
in China

# PROGRAM

*Program sponsored by*

**FLUOR<sup>®</sup>**

October 12–13, 2011  
Pudong Shangri-La Hotel  
Shanghai, China

*Organized by*

**Bio<sup>®</sup>**  
BIOTECHNOLOGY  
INDUSTRY ORGANIZATION

*Co-organized by*

**ZKJI**  
ZJ INNOPARK  
张江高科技园区

# CONTENTS

PROGRAM OVERVIEW .....	3
SPONSORS .....	9
PROGRAM DETAILS .....	13
PRESENTATION SCHEDULES .....	31
EXHIBITORS .....	34
CONFERENCE FLOOR PLANS .....	36

*To download the BIO China company profiles, go to  
[www.bio.org/biochina/profiles](http://www.bio.org/biochina/profiles).*

*Organized by*



*Co-organized by*



# PROGRAM OVERVIEW

WEDNESDAY, OCTOBER 12, 2011

8:00 a.m.–10:25 a.m. Opening Ceremony & Keynote Session

*Speakers:*

- James C. Greenwood, President and CEO, Biotechnology Industry Organization
- 
- Remarks from Chinese Government Officials

*Keynote Speakers:*

- The Honorable Elaine Chao, Former Secretary, US Department of Labor
- Qiyu Chen, President, Fosun Pharma

10:30 a.m.–12:00 p.m. Exhibit Hall Open

10:30 a.m.–12:00 p.m. Partnering Meeting Times Available

10:30 a.m.–11:55 a.m. Company Presentations

10:30 a.m.–11:55 a.m. Zhangjiang Session I

**“Biopharma Development in China and International Cooperation”**

*Moderator:*

- William R. Keller, Vice General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.

*Keynote Speakers:*

- Mr. Qing Li, Ministry of Health, Medicine and Technology Development Research Center
- Mr. Luke Miels, President of Roche Pharma Asia-Pacific
- Mr. Lanzhong Wang, General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.

*Panel + Q&A:*

- Mr. Yuliang Huang, Chief Executive Officer, Generon (Shanghai) Corporation
- Mr. Douglas Khoo, Technology Manager, Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd.
- Mr. Jun Ren, Chief Executive Officer, NewsummitBiopharma Group
- Mr. Wansong Sun, Director of Investment Promotion Agency, Ministry of Commerce, People's Republic of China
- Dr. Dave Tapolczay, Chief Executive Officer, Medical Research Council Technology Ltd.
- Mr. David Wilkinson, Global Product Director, AstraZeneca R&D Charnwood
- Dr. Yichun Zhu, Dean of College of Pharmacy, Fudan University

# PROGRAM OVERVIEW

WEDNESDAY, OCTOBER 12, 2011

- 10:30 a.m.– 11:55 a.m. Business Development Panel  
**“China—It’s a Big Deal”**  
*Moderator:*
- Bernard Ng, Managing Director, Transaction Advisory Services (China), Ernst & Young
- Panelists:*
- Frank K. Au, Chief Executive Officer, Cowen and Company, Asia
  - Charles Hsu, PhD, MBA, Venture Partner, Mustang Ventures
  - Mark Lotter, Chief Executive Officer, China Operations, SciClone Pharmaceuticals & Former CEO, NovaMed Pharmaceuticals
  - Gary S. Titus, Chief Financial Officer, SciClone Pharmaceuticals, Inc.
- 12:00 p.m.–1:00 p.m. Networking Lunch
- 1:00 p.m.–5:25 p.m. Partnering Meeting Times Available
- 1:00 p.m.–5:25 p.m. Company Presentations
- 1:00 p.m.–5:30 p.m. Exhibit Hall Open
- 1:00 p.m.–2:25 p.m. Zhangjiang Session II  
**“Innovation in Zhangjiang”**  
*Moderator:*
- Dr. Li Chen, President and CEO, Hua Medicine Co. Ltd.
- Panel + Q&A:*
- Mr. George Baeder, Partner and Vice President, Monitor Group Asia
  - Mr. Leon Chen, Partner, Fidelity Asia Growth
  - Dr. Samantha Du, Chief Executive Officer, Hutchison MediPharma Limited (HMPL)
  - Dr. Xin Hui, Chief Executive Officer, ShangPharma Group Company
  - Mr. Lingshi Tan, General Manager, Pfizer (China) Research and Development Co., Ltd., China
  - Dr. Tony Zhang, Vice President of Global External R&D, Asia, Eli Lilly and Company
- 1:00 p.m.–2:25 p.m. Intellectual Property Panel  
**“Protection of Biotechnology Inventions in China, US and Europe: A Comparative Perspective”**  
*Moderator:*
- Thomas T. Moga, Of Counsel, Shook, Hardy & Bacon LLP
- Panelists:*
- Jasmine Chambers, Deputy Administrator for External Affairs at the United States Patent and Trademark Office
  - Francisco Fernandez y Branas, Director Biotechnology, European Patent Office
  - Chris Sappenfield, Senior Counsel, Ibis Biosciences, Inc.
  - Zhang Qingkui, Director General, Pharmaceutical and Biotech Examination Department, State Intellectual Property Office, People's Republic of China

# PROGRAM OVERVIEW

WEDNESDAY, OCTOBER 12, 2011

- 2:30 p.m.–3:55 p.m. Intellectual Property Panel  
**“Effective IP Mechanisms for Bringing Biopharmaceuticals to Market”**  
*Moderator:*
- Jonathan Zhuang Yuan, Managing Partner, US & European IP Practice, Shangcheng & Partners
- Panelists:*
- Haiyan Chen, PhD, JD, Senior Patent Counsel, GlaxoSmithKline R&D China
  - Jeffrey D. Hsi, Partner, Edwards Angell Palmer & Dodge, LLP
  - Joseph P. Taormino, PhD, Partner, Co-leader of Biotech Group, Hoffman Eitle
  - Yang Xu, PhD, JD, Chief Patent Counsel
- 2:30 p.m.–3:55 p.m. Health & Regulatory Issues Panel  
**“Navigating Changes in China's Registration & Regulatory Process”**  
*Moderator:*
- Romi Singh, Executive Director, Regulatory Affairs, Amgen, Inc.
- Panelist:*
- He Bai, Official, Drug Registration Department, SFDA
  -
- 4:00 p.m.–5:25 p.m. Intellectual Property Panel  
**“Encouraging Innovation through Robust Patent Enforcement”**  
*Moderator:*
- Frank S. DiGiglio, Managing Partner, Scully Scott Murphy & Presser PC
- Panelists:*
- Brian P. Barrett, RPh, JD, Senior Director, Assistant General Patent Counsel, Eli Lilly and Company
  - Zhonglin He, Senior Judge and Director, Judicial Affairs Office on Hong Kong, Macao & Taiwan, Supreme People's Court, People's Republic of China
  - Tina Tai, Patent Attorney, Attorney-at-law, Assistant General Manager, China Patent Agent (H.K.) Ltd.
- 5:45 p.m.–6:30 p.m. Buses depart from the Shangri-La River Wing Entrance
- 6:00 p.m.–8:00 p.m. Gala Reception: Shanghai Science and Technology Museum  
*Sponsored by Abbott*

# PROGRAM OVERVIEW

THURSDAY, OCTOBER 13, 2011

- 8:00 a.m.–8:25 a.m.      Networking Continental Breakfast
- 8:30 a.m.–9:25 a.m.      **Keynote Session**  
*Speaker:*
- Dr. Jörg Reinhardt, CEO, Bayer HealthCare
- 9:30 a.m.–10:55 a.m.      Partnering Meeting Times Available
- 9:30 a.m.–10:55 a.m.      Company Presentations
- 9:30 a.m.–10:45 a.m.      Exhibit Hall Open
- 9:30 a.m.–10:55 a.m.      Health & Regulatory Issues Panel  
**“A Bold Initiative to Support Biotechnology—China's 12th Five-Year Plan”**  
*Moderator:*
- Richard Davies, Vice President & General Manager, Japan & Asia Pacific, Amgen, Inc.
- Panelists:*
- George Baeder, Partner and Vice President, Monitor Group Asia
  - Samantha Du, PhD, Chief Executive Officer, Hutchinson MediPharma Limited (HMPL)
  - Peter H. Khoury, PhD, MBA, Vice President, Global Marketing, Baxter HealthCare, Vaccines
  - Song Ruilin, Executive President, SINO-PhIRDA
  - Jean-Denis Shu, Medical Affairs Director, Shenzhen Sanofi Pasteur Biological Products Co. Ltd, China
- 9:30 a.m.–10:55 a.m.      Vaccines & Global Health Panel  
**“Innovations in Prevention & Treatment: Global Trends in Vaccine Platform Development”**  
*Moderator:*
- Phyllis Arthur, Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy, Biotechnology Industry Organization (BIO)
- Panelists:*
- Stephen W. Cook, PhD, Vice President, Head of Worldwide Vaccine Registration Management & Regulatory Operations, GlaxoSmithKline Biologicals
  - Stanley C. Erck, President and CEO, Novavax, Inc.
  - Jueren Lou, Director of Technology, Shanghai Biological Product Research Institute

# PROGRAM OVERVIEW

THURSDAY, OCTOBER 13, 2011

- 11:00 a.m.–12:25 p.m. Health & Regulatory Issues Panel  
**“Challenges and Opportunities for Clinical Development in China”**  
*Moderator:*
- Dan Zhang, MD, MPH, Co-Founder & CEO, Fountain Medical Development Corp.
- Panelists:*
- Nathaniel Brown, MD, Chief Medical Officer and SVP, Clinical Development, Presidio Pharmaceuticals
  - Bing Yan, MD, MBA, Head of Clinical Development Asia & China Vaccines Lead, Emerging Markets, Pfizer, Inc.
  -
- 11:00 a.m.–12:25 p.m. Business Development Panel  
**“Chinese Start-Ups”**  
*Moderator:*
- Howard Liang, Senior Biotech Analyst, Leerink Swann
- Panelists:*
- Leon Chen, Partner, Fidelity Asia Growth Partners
  - James Li, Partner, KPCB China
  - Dajun Yang, MD, PhD, President and CEO, Ascentage Pharma Group Corporation
- 12:30 p.m.–1:30 p.m. Networking Lunch
- 1:30 p.m.–2:55 p.m. Partnering Meeting Times Available
- 1:30 p.m.–3:00 p.m. Company Presentations
- 1:30 p.m.–3:00 p.m. Exhibit Hall Open
- 1:30 p.m.–2:55 p.m. Health & Regulatory Issues Panel  
**“Balancing Biosimilar Expansion and Innovation—  
China's Regulatory Landscape for Large Molecules”**  
*Moderator:*
- Shaoyu Chen, Managing Director, China Food & Drug Practice, Covington & Burling LLP
- Panelists:*
- John Zhaolong Gong, PhD, MD, SVP and Chief Technology Officer, JOINN Laboratories
  - Li Jie, Director, China, Worldwide Regulatory Strategy, Pfizer, Inc.
  - Wassim Nashabeh, PhD, Global Head, Technical Regulatory Policy & Strategy, Genentech, A member of the Roche Group
  - Li Weiping, Regulatory Affairs Director, Xian-Janssen Pharmaceutical Ltd.

# PROGRAM OVERVIEW

THURSDAY, OCTOBER 13, 2011

- 1:30 p.m.–2:55 p.m. Vaccines & Global Health Panel  
**“Healthcare Reform Implementation in China:  
Attaining New Levels of Prevention through Public-Private Partnerships”**  
*Moderator:*
- James McGregor, Senior Counselor, APCO Worldwide China
- Panelists:*
- Sam Liao, Asia Head of Business Development & Licensing, Novartis Vaccines & Diagnostics
  - Michel Vounatsos, President, Merck Sharp & Dohme (MSD)-China
  - Bing Yan, MD, MBA, Head of Clinical Development Asia & China Vaccines Lead, Emerging Markets, Pfizer, Inc.
- 2:00 p.m.–2:55 p.m. Business Development Panel  
**“A 360 on China's Healthcare Capital Markets”**  
*Panelists:*
- Ross Hammerman, Director, Healthcare Investment Banking, Citigroup
- Ling Zhang, Director, Citigroup Global Markets Asia Ltd.
- 3:00 p.m.–4:00 p.m. Closing Reception with Fosun Pharma  
*Sponsored by Fosun Pharma*

*Schedule subject to change.*

# SPONSORS

*BIO thanks the following sponsors for their support.*

## CO-ORGANIZER

# ZK JI

ZJ INNOPARK  
张江高科技园区

## BIO DOUBLE HELIX SPONSORS



# SPONSORS

## BIO HELIX SPONSORS



## CONFERENCE SPONSORS



# SPONSORS

## CONFERENCE SPONSORS



LEERINK SWANN

The Healthcare Investment Bank

**Lonza**

MONITOR

ROPES&GRAY



SCULLY SCOTT MURPHY & PRESSER PC  
SECURING INGENUITY®  
PATENTS • TRADEMARKS • COPYRIGHTS



Shook,  
Hardy &  
Bacon LLP  
www.shb.com



TRANSPERFECT



## LOCAL EVENT SPONSOR



## ASSOCIATION SPONSORS

Beijing Pharma and Biotech  
Center (BPBC)



SINO-PHIRDA

The Chinese Biopharmaceutical  
Association

# SPONSORS

## MEDIA PARTNERS



GBI

**JAICASIABIO**network

**WICON** PHARMA CHINA  
[www.pharmachinaonline.com](http://www.pharmachinaonline.com)

BioPharma Insight

## Opening Ceremony

- James C. Greenwood, President and CEO, Biotechnology Industry Organization
- Remarks from Chinese Government Officials

## Opening Keynote Session

### SPEAKERS:

- The Honorable Elaine Chao, Former Secretary, US Department of Labor
- Qiyu Chen, President, Fosun Pharma

---

### Who's Who

---

**James C. Greenwood** is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Since his appointment in January of 2005, he has markedly enhanced the trade association's capacity – increasing both its staff and budget by nearly fifty percent. BIO is now a world class advocacy organization playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally. Mr. Greenwood represented Pennsylvania's Eighth District in the US House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment.

From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's vast jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies. Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981–86) and six years in the Pennsylvania Senate (1987–1992). Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield, Pennsylvania.

**The Honorable Elaine Chao** – The nation's 24<sup>th</sup> Secretary of Labor and the first Asian-American woman appointed to the President's cabinet in our nation's history, speaker Elaine Chao is an influential public figure who has made a positive difference in the lives of America's workforce. After arriving in the United States at the age of eight speaking no English, Elaine Chao's experience transitioning to a new country inspired her to dedicate her life to ensuring that workers have the opportunity to build better lives for themselves and their families.

Under her leadership, the US Department of Labor achieved record results in protecting the health, safety, wage, and retirement security of the nation's workforce. As the first Secretary of Labor in the 21<sup>st</sup> century, Elaine L. Chao increased focus on improving the competitiveness of America's workforce. She was a key participant in the U.S-China Strategic Economic Dialogue, the Cabinet to Cabinet forum established by the presidents of the two nations. She also led the US Delegation to the Closing Ceremony of the Beijing Olympics in 2008.

As President and Chief Executive Officer of United Way of America, she restored public trust and confidence in one of our nation's largest institutions of private charitable giving after it had been tarnished by financial mismanagement and abuse. As director of the Peace Corps, she established the first programs in the Baltic nations and the newly independent states of the former Soviet Union. Her government service also includes serving as deputy secretary at the US Department of Transportation, the number two official in a department of over 110,000 people and a budget of over \$30 billion.

A banker with Citicorp and Bank of America prior to her government service, she received an MBA from the Harvard Business School and an economics degree from Mt. Holyoke College. She is the recipient of 34 honorary doctorate degrees. Currently, she is a Distinguished Fellow in a Washington think tank and a FOX News contributor.

**Qiyu Chen** joined Fosun Pharma in 1994, he started his career at the Research and Development Department of Shanghai RAAS Blood Product Co. Ltd. After joining the Fosun Group, Mr. Chen worked as Manager of the industry development department of Group, Vice General Manager, Chief Financial Officer, Secretary to the Board, and Executive Vice President, before taking office as President of the company.

Mr. Chen is President of Shanghai BioPharmaceuticals Industry Association, Director of Shanghai Genetics Society, Vice Chairman of the fourth council of China Medicinal Biotech Association, Member of the sixth session of Youth Union of Putuo District and Shanghai Government Procurement Evaluation Expert.

Mr. Chen was awarded a Bachelor's degree in genetic engineering in 1993 from Fudan University and an Executive Master of Business Administration degree in 2005 from China Europe International Business School.

## ***Business Development Panel***

### **China—It's a Big Deal**

M&A and drug development deals between Western and Chinese companies are on the rise. This session will profile one of the most high-profile China-West collaborations of the past year. The principal dealmakers from both companies will be on hand to discuss the deal's development and will offer candid advice for companies pursuing China-West collaborations.

**MODERATOR:**

- Bernard Ng, Managing Director, Transaction Advisory Services (China), Ernst & Young

**PANELISTS:**

- Frank K. Au, Chief Executive Officer, Cowen and Company, Asia
- Charles Hsu, PhD, MBA, Venture Partner, Mustang Ventures
- Mark Lotter, Chief Executive Officer, China Operations, SciClone Pharmaceuticals, Inc. and Former CEO, NovaMed Pharmaceuticals
- Gary S. Titus, Chief Financial Officer, SciClone Pharmaceuticals, Inc.

---

*Who's Who*

---

**Bernard Ng** – Please see biography on [bio.org/biochina](http://bio.org/biochina) and on the updated errata sheet.

## ***Zhangjiang Session I***

### **Biopharma Development in China and International Cooperation**

China as one of the world's fastest growing emerging pharmaceutical markets, its international position and influence have been rising, also has attracted a growing number of multinational pharmaceutical companies and research institutions to settle down and develop in China, with the following great opportunities and challenges when the international cooperation happened between China and worldwide in bio-pharmaceutical industry. The Chinese government pays great attention to the development of pharmaceutical industry and takes advantages of opportunities and challenges of the time. The bio-pharmaceutical industry has been positioned as one of the national strategic and emerging industries, the Chinese government also established fund for major new drugs research and development, aims to give a special support to the enterprises with innovation and participation in international cooperation, and to promote bio-pharmaceutical industry with rapid and healthy development. Zhangjiang Hi-Tech Park is one of the earliest National Hi-Tech Park with the leading bio-pharmaceutical industry as the major industry. When Zhangjiang is hosting dual development opportunities from international and local bio-pharmaceutical industry, the concept of "innovation and integration" will positively undertake and promote the bio-pharmaceutical industry. With the cooperation with BIO, the first BIO China conference will be held in Pudong Shanghai. We have planned and organized two workshops separately in AM and PM in 12th Oct, 2011. We will share with all the participants the national strategic planning for Chinese bio-pharmaceutical industry, the development of Zhangjiang Bio-Pharmaceutical industry cluster, and the classic international successful case studies of settled down in Zhangjiang, also explore with you how to promote the global bio-pharmaceutical industry to flourish through enhanced the international cooperation.

#### MODERATOR:

- William R. Keller, Vice General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.

#### KEYNOTE SPEAKERS:

- Mr. Qing Li, Ministry of Health, Medicine and Technology Development Research Center
- Mr. Luke Miels, President of Roche Pharma Asia-Pacific
- Mr. Lanzhong Wang, General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.

#### PANEL + Q&A:

- Mr. Yuliang Huang, Chief Executive Officer, Generon (Shanghai) Corporation
- Mr. Douglas Khoo, Technology Manager, BoehringerIngelheim Shanghai Pharmaceuticals Co., Ltd.
- Mr. Jun Ren, Chief Executive Officer, NewsummitBiopharma Group
- Mr. Wansong Sun, Director of Investment Promotion Agency Ministry of Commerce, People's Republic of China
- Dr. Dave Tapolczay, Chief Executive Officer, Medical Research Council Technology Ltd.
- Mr. David Wilkinson, Global Product Director, AstraZeneca R&D Charnwood
- Dr. Yichun Zhu, Dean of College of Pharmacy, Fudan University

---

#### *Who's Who*

---

**William R. Keller** has been a director of Alexion since December 2009. Mr. Keller is the founder of Keller Pharma Consultancy, a pharmaceutical consulting firm in China. He is also a senior consultant to the Shanghai Foreign Investment Development Board and the deputy general manager of Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd. From 2007 to September 2009, Mr. Keller was the chairman of HBM Biomed China Partners, a specialized venture capital organization dedicated exclusively to life sciences

---

WEDNESDAY, OCTOBER 12, 2011

10:30 AM–11:55 AM

SHANGHAI ROOM

---

in China. From 1994 to 2003, Mr. Keller was the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. From 1974 to 2003, Mr. Keller served in various positions at Roche Group in South America and Asia. Mr. Keller is the honorary president of the R&D-based Pharmaceutical Association in China, the vice chairman of the Shanghai Association of Foreign Investment Enterprises and holds directorships in Cathay Industrial Biotech Ltd., Shanghai Fosun Pharmaceutical Development Co. Ltd., TaiGen Biotechnology Co., Ltd., each of which are privately held, and China Nuokang Biopharmaceutical Inc., which is a NASDAQ listed company. Mr. Keller graduated from the School of Economics and Business Administration (Zurich) and is Honorary Citizen of Shanghai.

## ***Zhangjiang Session II***

### **Innovation in Zhangjiang**

As a passport to China innovation, ZJ High-Tech Park played a pivotal role in leading biotech and pharmaceutical development in China, and in this session you will meet leaders from the different sectors in Zhangjiang, who have contributed to the establishment of the innovation ecosystem in Shanghai. While it is important for you to hear their successful experiences and lessons learned in our session, you can expect more: they will collectively address a frequently asked Big Question "when can China become a leader in drug discovery innovation and what does it take to make China discovery far more productive than what we have done in the last two decades in the western world?"

**MODERATOR:**

- Dr. Li Chen, President and CEO, Hua Medicine Co. Ltd.

**PANEL + Q&A:**

- Mr. George Baeder, Partner and Vice President, Monitor Group Asia
- Mr. Leon Chen, Partner, Fidelity Asia Growth
- Dr. Samantha Du, Chief Executive Officer, Hutchison MediPharma Limited (HMPL)
- Dr. Xin Hui, Chief Executive Officer, ShangPharma Group Company
- Mr. Lingshi Tan, General Manager, Pfizer (China) Research and Development Co., Ltd., China
- Dr. Tony Zhang, Vice President of Global External R&D, Asia, for Eli Lilly and Company

---

*Who's Who*

---

**Dr. Li Chen** – Please see biography on [bio.org/biochina](http://bio.org/biochina) and on the updated errata sheet.

## *Intellectual Property Panel*

### Protection of Biotechnology Inventions in China, US and Europe: A Comparative Perspective

The panel will compare what can be patented and the scope of protection in China, EU and the US including protections that are afforded to plants (utility, PVP, etc.). The panel will also explore the impact of changes in patent laws or regulations in each of these jurisdictions on biotechnology patenting. The panel will consider aspects of the Third Patent Law Amendments in China, patent reform in the US, and the European Directive and other related policies and their impact on biotechnology patenting.

#### MODERATOR:

- Thomas T. Moga, Of Counsel, Shook, Hardy & Bacon LLP

#### PANELISTS:

- Jasmine Chambers, Deputy Administrator for External Affairs, United States Patent and Trademark Office
- Francisco Fernandez y Branas, Director Biotechnology, European Patent Office
- Chris Sappenfield, Senior Counsel, Ibis Biosciences, Inc.

---

*Zhang Qingkui, Director General, Pharmaceutical and Biotech Examination Department, State Intellectual Property Office of the People's Republic of China* *Who's Who*

---

**Thomas T. Moga** is a patent attorney with the Washington DC office of Shook, Hardy & Bacon where he focuses on patent preparation and prosecution as well as on licensing, litigation and dispute resolution. His primary experience is in development and enforcement of domestic and foreign patent portfolios for US pharmaceutical and chemical companies. Mr. Moga holds a BS degree in biochemistry and a degree in law. He is an experienced patent prosecutor in the chemical, biochemical and pharmaceutical arts and has been qualified and has testified as an expert witness in patent disputes. Mr. Moga is the author of a multi-volume treatise on patent law in Asia.

Mr. Moga has been involved in intellectual property training programs both at home and abroad. He spent part of 1997 as a Fulbright Scholar in China where he taught patent law at Jilin University and acted as an instructor for patent examiners at China's State Intellectual Property Office. Mr. Moga was a visiting foreign expert in law at Xiamen University, China. He is an adjunct professor of law at the University of Toledo School of Law and is on the Board of Advisors for the Cooley School of Law's LLM program in intellectual property.

## ***Health & Regulatory Issues Panel***

### **Navigating Changes in China's Registration & Regulatory Process**

To successfully introduce a new product in China requires in-depth knowledge of Chinese regulatory requirements. At the same time, sponsors are increasingly looking to conduct trials simultaneously in multiple countries, putting a premium on a regulatory system that has strong standards that are similar among countries. How are changes in China's regulatory structure supporting increased innovation? How is the SFDA operating in a manner to foster both more rapid drug development to improve public health and internationally simultaneous trials? Are there constraints that make changes to the registration and regulatory process more difficult to achieve? In this session, experienced representatives from multinational and local Chinese companies will discuss the registration process for products manufactured in China, import licensing issues for products exported to China, and the connotations of these processes for innovative global drug development.

MODERATOR:

- Romi Singh, Executive Director, Regulatory Affairs, Amgen, Inc.

PANELISTS:

- He Bai, Official, Drug Registration Department, SFDA

---

*Who's Who*

---

**Dr. Romi Singh** has over 14 years of extensive scientific and management experience in top-tier pharmaceutical and biotechnology companies such as Burroughs/GlaxoWellcome, Merck, and Amgen. His experience spans across the spectrum of drug development-basic research to regulatory/clinical sciences. He is well published and recognized in field of drug metabolism and is an expert on clinical trials and drug registrations in developing countries. Dr. Singh is currently an Executive Director of Global Regulatory & Safety heading the group that supports expansion into new emerging markets in Latin America, Asia, Central& Eastern Europe. He holds an undergraduate degree from St. Stephen's College, doctorate from the University of Kansas, and has received postdoctoral training from the University of Washington.

## ***Intellectual Property Panel***

### **Effective IP Mechanisms for Bringing Biopharmaceuticals to Market**

China's investment in its 12<sup>th</sup> Five-Year Plan has resulted in a significant boost in biotechnology R&D. Innovative technologies and discoveries are resulting from investment in biotechnology. China's nascent innovative biopharmaceutical sector will be faced with challenges and opportunities for bringing their products to market. A panel of experts will explore various IP mechanisms for protecting research data including trade secret and regulatory data protections as means for bringing discoveries to market. The panel will also look to systems in the US (Hatch Waxman) and in Europe (Biosimilars) as possible mechanisms for approval of biopharmaceuticals.

#### MODERATOR:

- Jonathan Zhuang Yuan, Managing Partner, US & European IP Practice, Shangcheng & Partners

#### PANELISTS:

- Haiyan Chen, PhD, JD, Senior Patent Counsel, GlaxoSmithKline R&D, China
- Jeffrey D. Hsi, Partner, Edwards Angell Palmer & Dodge, LLP
- Joseph P. Taormino, PhD, Partner, Co-leader of Biotech Group, Hoffman Eitle
- Yang Xu, PhD, JD, Chief Patent Counsel

---

#### *Who's Who*

---

**Jonathan Zhuang Yuan** is a US patent attorney and an attorney at law admitted in New York and Connecticut. He is a partner at Shangcheng & Partners. Prior to joining Shangcheng, he was a partner at one of the largest IP law firms in China as well as the firm's Shanghai office General Manager. Before that, Mr. Yuan was based in Los Angeles as an attorney with a large international law firm and a representative of the firm's Shanghai office. Mr. Yuan started his legal career in a well-known IP boutique in New York. Prior to pursuing his legal career, Mr. Yuan was a molecular biologist at Cold Spring Harbor Laboratory on Long Island, New York.

Mr. Yuan's practice focuses on patent counseling, strategies, search and analysis, opinion, procurement, patent litigation/ITC 337 actions and licensing in technology fields including life sciences, pharmaceuticals, material sciences, medical devices and electronics. He counsels various clients ranging from multinational companies to start-ups and academic institutions.

Mr. Yuan is an author/co-author of numerous publications. Selected publications include an article on China's new patent law and rules (featured on cover of *China Law and Practice*, 2010), Chapter of "Patent Law" in the book *Doing Business in China* (2010), a research article featured on cover of *Cell* (May 1998) as well as other peer-reviewed research articles in journals such as *Development*, *ProcNatlAcadSci USA*, and *Genes & Development*. Mr. Yuan is frequently invited to speak in international IP conferences and webinars. He was the key organizer behind several high-profile IP forums in China.

Mr. Yuan received his JD from St. John's University School of Law in New York. He attended a PhD program in cell and molecular biology and completed the courses of the program at City University of New York, Graduate School and University Center. He received his MA in biology from City College of New York and his BS from in biology Peking University.

Mr. Yuan is a member of American Bar Association, New York State Bar Association, Connecticut Bar Association, American Intellectual Property Law Association (AIPLA) and Association of University Technology Managers (AUTM). Languages: Chinese and English.

## *Intellectual Property Panel*

### Encouraging Innovation through Robust Patent Enforcement

A panel of experts will explore how enforcement of IP can support the goals of the 12th Five-Year plan in a competitive global economy. The panel will explore the challenges to enforcement in face of limited resources and will compare and contrast enforcement in the US and China.

MODERATOR:

- Frank S. DiGiglio, Managing Partner, Scully Scott Murphy & Presser PC

PANELISTS:

- Brian P. Barrett, RPh, JD, Senior Director, Assistant General Patent Counsel, Eli Lilly
- Zhonglin He, Senior Judge & Director, Judicial Affairs Office on Hong Kong, Macao & Taiwan, Supreme People's Court of the People's Republic of China
- Tina Tai, Patent Attorney, Attorney-at-law, Assistant General Manager, China Patent Agent (H.K.) Ltd.

---

*Who's Who*

---

**Frank S. DiGiglio** received his BS in Biology from Boston College in 1975 and his JD from St. John's University School of Law in 1982. He was admitted to the N.Y. State Bar in 1983, the US District Court, Southern and Eastern Districts of New York, New York State Court of Appeals for the Second Circuit and US Court of Appeals, and Federal Circuit. Mr. DiGiglio is registered to practice before the US Patent and Trademark Office and is a member of the New York State Biotechnology Association, NYIPA and AIPLA. Mr. DiGiglio is an Adjunct Professor at Benjamin N. Cardozo School of Law (Yeshiva University) in Pharmaceutical and Biotechnology Patent Law. Mr. DiGiglio is experienced in patent and trademark litigation; extensive interference practice; Federal Circuit appeal practice; with technical emphasis in biotechnology, biochemistry and pharmaceutical sciences.

## **Keynote Session**

SPEAKER:

- Dr. Jörg Reinhardt, Chief Executive Officer, Bayer HealthCare

---

*Who's Who*

---

**Dr. Jörg Reinhardt** has been Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee since August 15, 2010.

Dr. Jörg Reinhardt, born on March 11, 1956 in Homburg in the German state of Saarland, studied pharmaceutical sciences at Saarland University in Saarbrücken. After obtaining his doctorate in 1981, he started his career with Sandoz, a predecessor company of Novartis, in 1982, holding various managerial positions of increasing responsibility in research and development. He was appointed Head of Corporate Development in 1994.

After the formation of Novartis in 1996, he served as Head of Preclinical Development and Project Management before being appointed Global Head of Pharma Development in 1999. In November 2005 he was appointed CEO of the Vaccines & Diagnostics Division, Boston, United States. At the end of 2008, Reinhardt returned to Switzerland to become Chief Operating Officer (COO) of Novartis, a position he held until the end of January 2010. In this capacity Reinhardt was responsible for all four of the group's divisions as well as for Human Resources, IT, Corporate Affairs and Communications. He was also a member of the company's Executive Committee.

From 2000 until January 2010, Reinhardt also served as Chairman of the Board of Directors of the Genomics Institute of the Novartis Foundation in La Jolla, California. From 2001 through 2004 he was a member of the Supervisory Board of MorphoSys AG, Germany, which specializes in researching and developing monoclonal antibodies.

Furthermore he is a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

## ***Health & Regulatory Issues Panel***

### **A Bold Initiative To Support Biotechnology— China’s 12th Five-Year Plan**

China’s recently announced 12th Five-Year Plan provides considerable support for biotechnology innovation. This plan, which aims to support both the development and manufacture of new biotechnology products, holds substantial promise to elevate China’s position and leadership in the industry. What does the government support for biotechnology portend for the sector? What are the various forms of support that will be created? Which are the areas of greatest need? This panel will discuss key aspects of China’s new initiative to support biotechnology.

**MODERATOR:**

- Richard Davies, Vice President & General Manager, Japan & Asia Pacific, Amgen, Inc.

**PANELISTS:**

- George Baeder, Partner and Vice President, Monitor Group Asia
- Samantha Du, PhD, Chief Executive Officer, Hutchinson MediPharma Limited (HMPL)
- Peter H. Khoury, PhD, MBA, Vice President, Global Marketing, Baxter HealthCare, Vaccines
- Song Ruilin, Executive President, SINO-PhIRDA
- Jean-Denis Shu, Medical Affairs Director, Shenzhen Sanofi Pasteur Biological Products Co. Ltd, China

---

*Who’s Who*

---

**Richard Davies** – Please see biography on [bio.org/biochina](http://bio.org/biochina) and on the updated errata sheet.

## ***Vaccines & Global Health Panel***

### **Innovations in Prevention & Treatment: Global Trends in Vaccine Platform Development**

This session will highlight global advances in technologies for new vaccines. Advances in recombinant, cellular and protein sciences as well as the availability of adjuvants may allow for significant improvements in vaccine technology. These advances could lead to both new and improved preventive vaccines through their ability to elicit broad antigenic responses and streamline manufacturing techniques. Panelists will discuss innovative vaccine programs as well as the challenges of development. Topics including clinical trial development and regulatory pathways for novel technologies will be discussed. In addition, companies will present scientific and clinical data and discuss their approaches to and uses for these new platforms.

#### **MODERATOR:**

- Phyllis Arthur, Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy, Biotechnology Industry Organization (BIO)

#### **PANELISTS:**

- Stephen W. Cook, PhD, Vice President, Head of Worldwide Vaccine Registration Management & Regulatory Operations, GlaxoSmithKline Biologicals
- Stanley C. Erck, President and CEO, Novavax, Inc.
- Jueren Lou, Director of Technology, Shanghai Biological Product Research Institute

---

#### *Who's Who*

---

**Phyllis Arthur** is Senior Director for Vaccines, Immunotherapeutics and Diagnostics Policy at the Biotechnology Industry Organization (BIO). In this role Ms. Arthur is responsible for working with member companies in vaccines, molecular diagnostics and bio-defense on policy, legislative and regulatory issues.

Ms. Arthur joined BIO in July 2009 as the Director of Healthcare Regulatory Affairs. Prior to joining BIO, she worked in numerous marketing and sales positions for Merck & Co Inc. in their Vaccine Division. Over her 16-year career in vaccines, Ms. Arthur launched several exciting new vaccines in the United States and internationally, including the first HPV vaccine GARDASIL. During her years in Marketing she worked closely with clinical and academic thought leaders in infectious diseases, oncology and public health. In addition, Ms. Arthur also led a large vaccine sales organization of over 75 representatives and managers covering 14 states.

Before graduate school, Ms. Arthur worked as a research assistant for two economists at the Brookings Institution in Washington, DC. There she conducted economic analyses related to savings and investment policies for the OECD countries.

Ms. Arthur received her BA in 1987 in Economics and International Politics from Goucher College and her MBA in 1991 from the Wharton School of Business at the University of Pennsylvania.

## ***Health & Regulatory Issues Panel***

### Challenges and Opportunities for Clinical Development in China

China is broadening its clinical trials infrastructure and improving safety, presenting new, innovative opportunities for clinical R&D. In this session, seasoned representatives from major CROs and drug development companies will discuss their experiences in China in key areas such as site selection, IRB approval processes, and content requirements to initiate trials in China. Experts in designing clinical studies conducted in China will address their experiences with the use of clinical data in China, and talk about what conducting studies in China means in terms of global development.

MODERATOR:

- Dan Zhang, MD, MPH, Co-Founder and CEO, Fountain Medical Development Corp

PANELISTS:

- Nathaniel Brown, MD, Chief Medical Officer and SVP, Clinical Development, Presidio Pharmaceuticals
- Bing Yan, MD, MBA, Head of Clinical Development Asia & China Vaccines Lead, Emerging Markets, Pfizer, Inc.

---

*Who's Who*

---

**Dr. Dan Zhang** has more than 10 year of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO with primary operation in China. Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, a US research arm of Sigma-Tau S.P.A., one of the largest Italy-based pharmaceutical firms with employees of 2300. Dr. Zhang managed the firm's entire clinical development program in North American market, including oncology, cardiovascular, CNS, and metabolic development projects, in addition to his global role of drug safety handling. Prior to his life at Sigma-Tau, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp.-the largest contract research organization (CRO) in the world, responsible for the planning and implementation of business development strategies in Greater China Area. He was also a member of Executive Operating Committee of Quintiles Transnational Corp. Dr. Zhang was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., a wholly-owned subsidiary of Quintiles Transnational Corp. Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc.

Over last ten years, Dr. Zhang established a strong working relationship with government and academic institutions in China. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. He was also a visiting professor at the Harbin Medical University of China. In addition, Dr. Zhang was a PhD advisor and consultant for then Shanghai Medical University in the field of Pharmacoeconomic study and clinical trials. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA).

Dr. Zhang received his pre-med training from Beijing University and received his MD from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master's degree in healthcare management in 1998 and is working on his PhD dissertation in the field of health economics and finance. Dr. Zhang has published several papers in the fields of medical research and health economics, and is a frequent speaker at various health care-related conferences.

## ***Business Development Panel***

### Chinese Start-Ups

A new wave of start-ups is moving forward pursuing innovative molecules. These companies frequently feature officers with US/EU experience in drug development, and offices and operations in both the US and China. The research being pursued has IP, as well as financing that is sourced in both the West and China. These companies face numerous challenges and choices: where to locate discovery research or development operations? Which market should be primary for development? Where should financing be pursued? What are investors looking for from these companies? How to look at financing, given the health of the IPO market in China? This panel will feature a number of CEOs of these new companies, as well as venture capitalists who are seeking to finance new companies in China.

#### MODERATOR:

- Howard Liang, Senior Biotech Analyst, Leerink Swann

#### PANELISTS:

- Leon Chen, Partner, Fidelity Asia Growth Partners
- James Li, Partner, KPCB China
- Dajun Yang, MD, PhD, President and CEO, Ascentage Pharma Group Corporation

---

#### *Who's Who*

---

**Dr. Howard Liang** was recognized by the Wall Street Journal's "Best on the Street" special report for stock picking in both biotechnology and pharmaceuticals in 2010, and in biotechnology in 2008. In addition, he was named #2 Stock Picker for Biotechnology in the 2011 FT/StarMine Analyst Awards.

Dr. Liang came to Leerink Swann from A.G. Edwards, where he was a senior biotechnology analyst. His prior Wall Street experience includes JMP Securities as a senior biotechnology analyst and Prudential Securities, where he was an associate to an Institutional Investor-ranked major pharma analyst.

Before that, Dr. Liang spent eight years at Abbott Laboratories, where he was a senior scientist and a member of one of the industry's leading structure-based drug discovery teams. During his career as a scientist, Dr. Liang authored papers in prestigious journals including Nature, Science, and Proceedings of the National Academy of Sciences.

Dr. Liang obtained his MBA and PhD in Biochemistry and Molecular biology, both from the University of Chicago. His undergraduate degree is a BS in Chemistry from Beijing University.

## ***Health & Regulatory Issues Panel***

### **Balancing Biosimilar Expansion and Innovation — China's Regulatory Landscape for Large Molecules**

China's expansion and improvement of health coverage for its population through health reform has considerable implications for the biosimilars market. Numerous Chinese companies are in this market segment, as are an increasing number of western companies. Likewise, China is taking dramatic steps to support the development of innovative molecules. How does China's regulatory system balance the development of both an expanding biosimilars segment along with innovative biotech development? What are key differences between the US, EU, and Chinese approaches? What are key global regulatory and market trends that impact biosimilars development? The regulation of both innovator and follow-on biotechnology products in the US, Europe, and China will be discussed by leading experts.

**MODERATOR:**

- Shaoyu Chen, Managing Director, China Food & Drug Practice, Covington & Burling LLP

**PANELISTS:**

- Li Jie, Director, China, Worldwide Regulatory Strategy, Pfizer, Inc.
- Wassim Nashabeh, PhD, Global Head, Technical Regulatory Policy & Strategy, Genentech, a member of the Roche Group
- John Zhaolong Gong, PhD, MD, SVP and Chief Technology Officer, JOINN Laboratories
- Li Weiping, Regulatory Affairs Director, Xian-Janssen Pharmaceutical Ltd.

---

*Who's Who*

---

**Shaoyu Chen** is a member of Covington & Burling's Food and Drug practice group and the Managing Director of its China food and drug practice. Mr. Chen has over 10 years' experience in food and drug law, including serving as assistant chief counsel at the United States Food and Drug Administration Office of Chief Counsel, as senior counsel at Amgen Inc., and as chief compliance counsel for GE Healthcare China. Mr. Chen represents pharmaceutical, biotechnology, medical device, food, dietary supplement, and cosmetic companies in matters before the China SFDA, the US FDA, and other government agencies. He regularly assists clients on legal and regulatory issues related to SFDA and FDA oversight, including those pertaining to preclinical research, clinical trial, marketing approval, advertising and promotion, manufacturing GMP, pharmacovigilance, import and export, and compliance with Foreign Corrupt Practices Act and China Anti-Unfair Competition Law.

## ***Vaccines & Global Health Panel***

### **Healthcare Reform Implementation in China: Attaining New Levels of Prevention through Public-Private Partnerships**

New government investments in urban health care reforms present an important opportunity to increase immunization rates across all ages. Local and multi-national vaccine developers, working with government entities and non-governmental organizations, are collaborating on new vaccines to conquer emerging infectious diseases. Panelists will share new developments in vaccines targeted to children, adolescents and adults for both rural and urban areas. Panelists will discuss their strategies, successes and challenges in their attempts to build productive relationships with their various partners. Opportunities for contract research and manufacturing, technology transfer and other partnering options will be evaluated and discussed as well as the role of government.

**MODERATOR:**

- James McGregor, Senior Counselor, APCO Worldwide China

**PANELISTS:**

- Sam Liao, Asia Head of Business Development & Licensing, Novartis Vaccines & Diagnostics
- Michel Vounatsos, President, Merck Sharp & Dohme (MSD)-China
- Bing Yan, MD, MBA, Head of Clinical Development Asia & China Vaccines Lead, Emerging Markets, Pfizer, Inc.

---

***Who's Who***

---

**James McGregor** is a senior counselor for APCO Worldwide in China, author of the bestselling book *One Billion Customers: Lessons from the Front Lines of Doing Business in China* and a veteran reporter for The Wall Street Journal. Prior to joining APCO, he served as chairman and CEO of a China-focused consulting and research firm for hedge funds. He also held previous roles as a senior advisor for Ogilvy Public Relations China and the China Managing Partner for GIV Venture Partners, a venture capital fund that focused on technology and Internet investments in China and India.

Mr. McGregor was a reporter in the Washington bureau of Knight-Ridder newspapers during the Reagan administration. After serving as the Taiwan bureau chief for The Wall Street Journal from 1987 to 1990 and China bureau chief from 1990 to 1994, he spent seven years building Dow Jones' media business in China as CEO of Dow Jones' China operations and an international vice president of the company. During this time, he established CNBC in China and created the Chinese language Web site of wsj.com, Dow Jones' Chinese-language newswire, Chinese stock-market indexes and the first weekly business-television show in China. He was also a Series A investor in Sohu.com and served on their board for several years, including during the company's NASDAQ listing. After successfully preventing Xinhua News Agency from obtaining a monopoly on financial information in China, he received the Barney Kilgore award, Dow Jones' highest employee accolade.

Mr. McGregor is a professional speaker, regular television and radio commentator and a contributor of essays and opinion articles for a variety of publications. He has more than 20 years of China experience and can speak and read Chinese. He was an active member of the Board of Governors of the American Chamber of Commerce in China (AmCham) for more than 10 years and served as chairman in 1996. He is currently chairman of the US Government Relations Committee for AmCham. He is also a member of the Council on Foreign Relations, a Global Council member of the Asia Society, a board member of the US-China Education Trust and a member of the National Committee on US-China Relations.

## ***Business Development Panel***

### **A 360 on China's Healthcare Capital Markets**

In a time where the global financial markets are in crisis, China's equities markets have increased more than tenfold in the last 6 years alone. As a young and evolving market, China has the unique opportunity to shape and define its presence in the global capital markets. The establishment of the ChiNext on the Shenzhen Stock Exchange (SZSE) opened the door for several biopharma start-ups in China. 2010 was characterized by an IPO boom in the Chinese markets, but is this sustainable? What trends can we expect to see emerge from China's nascent financial markets? Seasoned investment bankers will provide a 360 degree overview of the capital markets in China—past, present and future.

PANELISTS:

- Ross Hammerman, Director, Healthcare Investment Banking, Citigroup
- Ling Zhang, Director, Citigroup Global Markets Asia Ltd.

# PRESENTATION SCHEDULES

WEDNESDAY, OCTOBER 12, 2011

## ALPHABETICAL

<i>Company</i>	<i>Time</i>	<i>Room</i>
ABSize Inc.	3:30–3:55 pm	Changchun
AllinkyBiopharma	1:00–1:25 pm	Changchun
Alteogen Inc	2:30–2:55 pm	Shenyang
Astex Pharmaceuticals, Inc.	1:30–1:55 pm	Changchun
Biocrea GmbH	11:30–11:55 am	Changchun
Biomiga Diagnostics	2:30–2:55 pm	Changchun
BioView, Inc.	3:00–3:25 pm	Changchun
Debiopharm Group	5:00–5:25 pm	Shenyang
EGEN, Inc.	5:00–5:25 pm	Changchun
Genentech	11:00–11:25 am	Shenyang
GenorBioPharma Co., Ltd.	11:30–11:55 am	Shenyang
GlaxoSmithKline	10:30–10:55 am	Changchun
Gloria Pharmacueticals	4:00–4:25 pm	Changchun
Golden Biotechnology Corp.	2:00–2:25 pm	Changchun
Legacy Healthcare	2:00–2:25 pm	Shenyang
Micron Inc.	1:00–1:25 pm	Shenyang
Mycenax Biotech Inc.	4:00–4:25 pm	Shenyang
Neurodyn Inc. & Shanghai Innovative Research Center	3:00–3:25 pm	Shenyang
Neurotech USA, Inc.	3:30–3:55 pm	Shenyang
Pharming Group NV	1:30–1:55 pm	Shenyang
Roche	10:30–10:55 am	Shenyang
Sanofi Pasteur	11:00–11:25 am	Changchun
TransGenic Inc.	4:30–4:55 pm	Shenyang
WuXi AppTec	4:30–4:55 pm	Changchun

## CHRONOLOGICAL

<i>Time</i>	<i>Company</i>	<i>Room</i>
10:30–10:55 am	GlaxoSmithKline	Changchun
10:30–10:55 am	Roche	Shenyang
11:00–11:25 am	Genentech	Shenyang
11:00–11:25 am	Sanofi Pasteur	Changchun
11:30–11:55 am	Biocrea GmbH	Changchun
11:30–11:55 am	GenorBioPharma Co., Ltd.	Shenyang
1:00–1:25 pm	AllinkyBiopharma	Changchun
1:00–1:25 pm	Micron Inc.	Shenyang
1:30–1:55 pm	Astex Pharmaceuticals, Inc	Changchun
1:30–1:55 pm	Pharming Group NV	Shenyang
2:00–2:25 pm	Golden Biotechnology Corp.	Changchun
2:00–2:25 pm	Legacy Healthcare	Shenyang
2:30–2:55 pm	Alteogen Inc	Shenyang
2:30–2:55 pm	Biomiga Diagnostics	Changchun
3:00–3:25 pm	BioView, Inc.	Changchun
3:00–3:25 pm	Neurodyn Inc. & Shanghai Innovative Research Center	Shenyang
3:30–3:55 pm	ABSize Inc.	Changchun
3:30–3:55 pm	Neurotech USA, Inc.	Shenyang
4:00–4:25 pm	Gloria Pharmacueticals	Changchun
4:00–4:25 pm	Mycenax Biotech Inc.	Shenyang

# PRESENTATION SCHEDULES

4:30–4:55 pm	TransGenic Inc.	Shenyang
4:30–4:55 pm	WuXi AppTec	Changhun
5:00–5:25 pm	Debiopharm Group	Shenyang
5:00–5:25 pm	EGEN, Inc.	Changchun

# PRESENTATION SCHEDULES

THURSDAY, OCTOBER 13, 2011

## ALPHABETICAL

<i>Company</i>	<i>Time</i>	<i>Room</i>
Abbott	1:30–1:55 pm	Shenyang
Apexigen Inc.	10:00–10:25 am	Changchun
Bayer HealthCare Pharmaceuticals	9:30–9:55 am	Shenyang
Becton Dickinson	12:00–12:25 pm	Shenyang
Frontier Biosciences	2:30–2:55 pm	Changchun
HumabsBioMed SA	2:00–2:25 pm	Shenyang
IMPACT Therapeutics, Inc.	1:30–1:55 pm	Changchun
NB Health Laboratory Co.Ltd.	11:00–11:25 am	Changchun
Novo Nordisk	9:30–9:55 am	Changchun
Pfizer, Inc.	10:30–10:55 pm	Shenyang
Phage Pharmaceuticals, Inc.	11:00–11:25 am	Shenyang
Pharma Training Inc.	10:00–10:25 am	Shenyang
PhytoHealth Corporation	11:30–11:55 am	Changchun
ProCell Therapeutics, Inc.	2:30–2:55 pm	Shenyang
Shenzhen Chipscreen Biosciences Ltd.	10:30–10:55 am	Changchun
Thermostable Enzyme Laboratory Co.,Ltd.	12:00–12:25 pm	Changchun
Upstream Infinity, Inc.	11:30–11:55 am	Shenyang

## CHRONOLOGICAL

<i>Time</i>	<i>Company</i>	<i>Room</i>
9:30–9:55 am	Bayer HealthCare Pharmaceuticals	Shenyang
9:30–9:55 am	Novo Nordisk	Changchun
10:00–10:25 am	Apexigen Inc.	Changchun
10:00–10:25 am	Pharma Training Inc.	Shenyang
10:30–10:55 pm	Pfizer, Inc.	Shenyang
10:30–10:55 am	Shenzhen Chipscreen Biosciences Ltd.	Changchun
11:00–11:25 am	NB Health Laboratory Co.Ltd.	Changchun
11:00–11:25 am	Phage Pharmaceuticals, Inc.	Shenyang
11:30–11:55 am	PhytoHealth Corporation	Changchun
11:30–11:55 am	Upstream Infinity, Inc.	Shenyang
12:00–12:25 pm	Becton Dickinson	Shenyang
12:00–12:25 pm	Thermostable Enzyme Laboratory Co.,Ltd.	Changchun
1:30–1:55 pm	Abbott	Shenyang
1:30–1 55 pm	IMPACT Therapeutics, Inc.	Changchun
2:00–2:25 pm	HumabsBioMed SA	Shenyang
2:30–2:55 pm	Frontier Biosciences	Changchun
2:30–2:55 pm	ProCell Therapeutics, Inc.	Shenyang

To download the BIO China company profiles, go to  
[www.bio.org/biochina/profiles](http://www.bio.org/biochina/profiles).

# EXHIBITORS

**AWEX..... Booth 201**

**BioCentury..... Booth 307**

**CatalentPharma Solutions ..... Booth 209**

**Dongguan Songshan Lake Hi-tech Industrial Development Zone ..... Booth 211**

A Demonstration Area of Scientific Development, A Leading Area of Industrial Upgrading. An Eden for Technology Innovation, An Oasis for Talent Gathering.

**Fluor ..... Booth 202**

Fluor is the leading contractor of life sciences projects worldwide specializing in design-build-validate integration. Our Life Sciences business unit has been serving the pharmaceutical and biotech industry for more than 35 years.

**Foundation for Biomedical Research and Innovation ..... Booth 301**

The Foundation for Biomedical Research and Innovation (FBRI) serves as main coordinating organization of Kobe Lifescience Cluster and is heading the regional “Biomedical Kansai” network association - Japan’s largest cluster formation.

**Frontier BioSciences, Inc. .... Booth 200**

Frontier BioSciences, Inc., with AAALAC-accredited toxicology facility in Chengdu, China, and corporate headquarters in Maryland, provides a full spectrum of SFDA and US FDA GLP preclinical services to biotech and pharmaceutical companies worldwide.

**Health Ever Bio-Tech Co., Ltd..... Booth 108**

**Hong Kong Science and Technology Parks Corporation ..... Booth 101**

Hong Kong Science and Technology Parks Corporation is a statutory body dedicated to advancing innovation and technology in Hong Kong by providing world-class infrastructure and support services to technology companies.

**Hong Kong Zaotong International Group Co, Ltd. .... Booth 105**

**Kroll ..... Booth 306**

**Marks & Clerk ..... Booth 303**

The Bioscience Group at Marks & Clerk provides a full range of intellectual property service across our international office including Beijing, Hong Kong, Singapore, Malaysia and the UK.

**Nanjing Jiangning Science Park Life Science Town..... Booth 110**

**Shanghai Chempartner Co., Ltd..... Booth 204**

**Shanghai Medicilon Inc. .... Booth 111**

**Shanghai Patent & Trademark Law Office, LLC ..... Booth 311**

# EXHIBITORS

**Soft Flow ..... Booth 305**

**Transpacific IP ..... Booth 100**

Transpacific-IP is a leading IP management and asset development firm with offices across major Asian cities. Transpacific-IP is the go-to partner for companies seeking strategic IP advice and investments into Asia.

**VWR International ..... Booth 210**

Headquartered in Pennsylvania (USA) VWR International, LLC, is a global leading supplier and distributor of laboratory products, such as chemicals, furniture, equipment, instruments, apparel and consumables. It has worldwide sales of over USD \$3.6 billion in 2010.

**Yangtze River Pharmaceutical Group ..... Booth 102**

Yangtze River Pharmaceutical Group is one of the largest pharmaceutical corporations in China, with over 8000 employees and annual sales of over 25 billion RMB. Its corporate headquarters is based in Taizhou, Jiangsu Province. Yangtze has more than 20 affiliations as well as several R&D centers and manufacturing facilities located in Shanghai, Beijing, Nanjing, Guangzhou and Chengdu. Its US office and the first subsidiary outside of China have recently been established in San Francisco.


**Zhangjiang Innovation Park ..... Booth 207**

Zhangjiang Hi-Tech Park was established in 1992 as China's state-level high-tech industrial development zone. After seventeen years of accumulation and development through providing high value-added products and services with innovative core technologies to progressively replace the life cycle of traditional industries, represents the revolutionary transformation trend of China's economic development pattern.


# CONFERENCE FLOOR PLANS

## FLOOR PLAN

RIVER WING  
LEVEL 3




LEVEL 2



# CONFERENCE FLOOR PLANS

## FLOOR PLAN

GRAND TOWER  
LEVEL 3





BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.

***Published by***

Biotechnology Industry Organization  
1201 Maryland Ave., SW, Suite 900  
Washington DC, 20024  
202-962-9200  
<http://www.bio.org>

Any portion of this material may be reproduced with attribution to BIO © 2011 by the Biotechnology Industry Organization.

***Biotechnology Industry Organization***

James C. Greenwood, President & Chief Executive Officer

***Emerging Companies and Business Development***

Alan F. Eisenberg, Executive VP, Emerging Companies & Business Development  
John Craighead, PhD, Managing Director, Investor Relations & Business Development  
Jen Welch, CMP, Director, Meetings & Operations  
Wesley Triplett, Director, Business Development Marketing  
Robyn Song, Director, Event & Services Marketing, Business Development Department  
David Thomas, Director, Industry Research & Analysis  
Tamy Dalal, Senior Manager, Strategic Alliances & Business Development  
Bernadette Blake, Manager, Registration & Customer Service  
Joe Colangelo, Senior Manager, Business Development  
Celia Economides, MPH, Manager, Investor Relations  
Rena'e Grant, Manager, Partnering Programs & Investor Outreach

***Sponsorship and Membership***

Amy Finan, Vice President, Corporate Development & Marketing  
John Sloan, Managing Director, External Relations & Development  
Susanna Ling, Director, Sponsorship  
Jason Rupp, Director, Membership  
Beth Rosenkoetter, Senior Manager, Sponsorship  
Elizabeth Gaskins, Manager, Membership

***Privacy***

In accordance with its Privacy Policy, BIO does not sell or rent its customer information or usage data to third parties.







